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Abstract
Background: The aim of this study was to evaluate the psychometric properties of the Brazilian version of the Oral
Anticoagulation Knowledge (OAK) Test.
Methods: This study, conducted in an anticoagulation clinic, included 201 Brazilian participants aged over 18 years,
who had been using warfarin for more than two months. The reliability of the instrument was evaluated by assessing
internal consistency (Kuder-Richardson coefficient) and reproducibility (test-retest reliability). The validity was evaluated
by hypothesizing that there would be a positive correlation of moderate to strong intensity between the correctness
levels of the OAK Test and time within therapeutic range (TTR) values, which is a measure used to evaluate the quality of
oral anticoagulation.
Results: The instrument exhibited good psychometric properties. The total a Kuder-Richardson coefficient value was 0.
818 and intraclass correlation coefficient was 0.967. The validity revealed a strong positive correlation between the
values of the level of knowledge, as measured by the OAK Test and the TTR values (rs = 0.780).
Conclusion: The instrument proved to be a reliable and valid tool for evaluating the knowledge of Brazilian patients
on oral anticoagulation therapy with warfarin. This instrument may be incorporated into the practice of health care for
substantiating the structuring of educational activities to ensure the improvement of knowledge about the use of
warfarin, thereby increasing the effectiveness and safety of treatment.
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Background
Warfarin is an oral anticoagulant, coumarinic derivative
used worldwide for primary and secondary prophylaxis
of thromboembolism. Its efficacy and safety have been
widely studied for several indications through well-
conducted clinical trials. The indication of oral anticoa-
gulation is increasing due to population aging and the
consequent increase in the incidence of thromboembolic
diseases [1–5].
The management of warfarin is quite complex due to
its narrow therapeutic range and wide dose–response
variability. Among the interfering factors in the anti-
coagulant effect, we can cite the presence of genetic
polymorphisms, drug and dietary interactions of poten-
tial clinical significance, as well as changes in the
patient’s condition as some of the common ones [1, 6].
For proper dose management, laboratory monitoring
is conducted by means of the International Normalized
Ratio (INR) calculated from the prothrombin activity.
The target INR is considered between 2.00 and 3.00 for
most of warfarin indications. Subtherapeutic results were
related to the occurrence of venous thromboembolism
and higher values, to increased risk of bleeding [1]. To
evaluate the quality of anticoagulant therapy, the
percentage of time of INR in the therapeutic range is
calculated (time within therapeutic range; TTR), the
bleeding and mortality rates being significantly higher in
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patients with TTR values <60 %, in comparison with
those presenting TTR values >75 % [7].
Studies have indicated that higher levels of knowledge
regarding warfarin therapy are related to an improved
stability of INR and increased TTR values [6, 8]. It is
therefore essential that patients using warfarin have ad-
equate knowledge about the therapeutic objective (indi-
cation and effectiveness), the process of use (dosage,
therapeutic regimen, route of administration, and dur-
ation of treatment), safety (adverse events, precautions,
contraindications, and interactions), as well as the con-
servation of the drug [9]. In this sense, the evaluation of
the patient’s level of knowledge using validated instru-
ments becomes necessary for identifying deficiencies and
guide educational activities to create a continuous
system of quality improvement of patient monitoring
and safety [10].
Among the few validated tools to evaluate patients’
knowledge regarding the use of warfarin, we can high-
light the Oral Anticoagulation Knowledge (OAK) Test,
which was validated for use in the United States of
America [8] and Malaysia [11], and showed good
psychometric properties. The OAK Test was cross-
culturally adapted into Brazilian Portuguese, presenting
a semantic and conceptual equivalence of items in rela-
tion to the original version [12]. It is recommended that
the psychometric properties of this adapted version be
evaluated to ensure its validity and reliability to achieve
the proposed objectives [13]. Therefore, the present
study aimed at evaluating the psychometric properties of
the Brazilian version of the OAK Test.
Methods
Study design and setting
This is a methodological study designed according to the
recommendations outlined in the literature for the evalu-
ation and validation of the instrument in question [14].
This study was conducted in an anticoagulation clinic of a
university hospital located in Belo Horizonte, southeastern
Brazil, which is a regional reference center that offers
medium and high complexity health assistance.
Sample
The number of participants in the phases of test and
retest of the questionnaire was according to the recom-
mendation to include at least 10 respondents for each
question of the instrument under validation and 30 % of
the initial sample for retest [15]. Thus, the sample com-
prised 201 consecutive patients who were recruited
during the service office hours, were aged 18 years or
older, were Brazilians, and were on warfarin for at least
one year. For the retest, 60 of these patients were ran-
domly selected for a new interview that was conducted
within two to three months after the first interview, a
period equal to that used in the study in which the ori-
ginal version of the OAK Test was developed [8]. It is
noteworthy that the correct answers to the test were not
revealed to the participants during any of the steps of
the study.
The instrument
The psychometric properties of the Brazilian version
of the OAK Test [12] were evaluated in this study by
employing internationally recognized methodology
[13, 16]. The instrument consists of 20 questions with
four possible answers, and only one correct option.
Each correct answer equals one point, leading to a
total score ranging from zero to 20 points. A higher
score indicates better level of knowledge about oral
anticoagulant therapy. Content and face validity were
evaluated by an expert committee that examined the
relevance of each item of the instrument and their ef-
fectiveness in measuring what they propose to meas-
ure, respectively [12].
Evaluation of psychometric properties
The evaluation of the psychometric properties of the
Brazilian version of the OAK Test included the analysis
of reliability and validity. The instrument’s reliability was
evaluated by assessing the internal consistency (Kuder-
Richardson coefficient) and reproducibility (test-retest
reliability).
For the analysis of the validity, it was hypothesized
that there would be a positive correlation, of moderate
to strong intensity, between the correctness levels of the
OAK Test and the TTR values.
Data collection
Data were collected between January to April 2015 by
means of individual interviews and consultation of the
hospital records of the participants. Instruments were ap-
plied for sociodemographic (age, sex, education, and in-
come) and clinical characterization (TTR), and the
Brazilian version of the OAK Test was administered. In-
terviews were conducted in a standardized manner by a
single interviewer to avoid interference with the respon-
dents’ answers. For TTR calculation, all patients’ INR
values obtained up to one year prior to interview were in-
terpolated by using the method proposed by Rosendaal.
This method assumes that there is a linear variation be-
tween values over time and the result correspond to the
percentage of time that anticoagulation has been within
therapeutic range [17].
Statistical analysis
The database was validated by double entry in the
EpiData program (version 3.1, EpiData Assoc, Denmark)
and analyzed using the Statistical Package for Social
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Sciences (SPSS for Windows, version 20.0, SPSS Inc.,
Chicago, IL). Descriptive analyses were performed for all
variables using measures of dispersion, frequency, and
central tendency.
Statistical analysis involved the evaluation of internal
consistency by the Kuder-Richardson coefficient, for
which values above 0.70 reflect a high degree of internal
consistency [15, 18]. Temporal stability was verified by
the values of the intraclass correlation coefficients (ICC)
of the OAK final score (quantitative variable with scores
varying from zero to 20) and by calculating the Cohen’s
Kappa coefficients for each dichotomized question of
the OAK Test (correctness and error).
We analyzed the Spearman correlation between the
OAK Test correctness levels and TTR to evaluate valid-
ity. The results were analyzed according to the following
classification: values below 0.30, even when statistically
significant, are of little clinical applicability, those be-
tween 0.30 and 0.50 are moderate, and those above 0.5
are of strong magnitude [19].
We also evaluated the correlations between the OAK
Test and age (years), educational level (years) and income
(Brazilian Reais). The gender-based comparison of the
OAK Test values was conducted using the Mann–Whit-
ney test, considering that the instrument did not show
normal distribution (Kolmogorov-Smirnov test, p < 0.001).
The statistical significance was declared at p = 0.05.
The description of knowledge was categorized accord-
ing to previous studies that used the same instrument
validated in other countries. The categories have in-
cluded scores <50 % as low, 50–75 % as average, and
>75 % as high level of knowledge regarding oral anticoa-
gulation [11, 20]. The quality of oral anticoagulation was
evaluated by stratified TTR, according to a previous
study, classified into three groups: <60 %, 60 %–75 %
and >75 % [7].
Results
The final analysis included 201 participants under treat-
ment with warfarin. The characteristics of the patients
have been presented in Table 1. The average number of
correct answers to the OAK Test was 63 % (±22)
(Table 1). The analysis of the instrument’s internal
consistency revealed a Kuder-Richardson coefficient of
0.818 for the total score. The exclusion of any instru-
ment items showed small changes in the Kuder-
Richardson coefficient, which ranged from 0.802 to
0.821 (Table 2).
The intraclass correlation coefficient of the total score
of the OAK Test was 0.967. Table 3 shows the Cohen's
Kappa coefficients of the test and retest performed, re-
vealing temporal stability ranging between good and per-
fect. By using a specific evaluation form, most items of
the instrument, 19 (95 %), were considered relevant for
the study population. Only item 2 was regarded irrele-
vant to the study in question, but it was maintained in
the instrument.
The validity revealed a strong positive correlation be-
tween the values of the level of knowledge measured by
the OAK Test and the TTR (rs = 0.780; p = 0.001). There
was a positive and weak correlation between the OAK
Test score and education (rs = 0.191; p = 0.007) and
income (rs = 0.170; p = 0.016). Other analyses were
performed and showed a negative but weak and non-
significant correlation between the OAK Test score and
age (rs = −0.116; p = 0.100). There was no association
between the OAK Test score and the gender of the par-
ticipants (Mann–Whitney Test, p = 0.182).
Discussion
This study systematically evaluated the psychometric
properties of the Brazilian version of the OAK Test [12].
The results of this evaluation demonstrated adequate













No formal education 8 (4)
Incomplete primary education 126 (63)
Complete primary education 28 (14)
High school 37 (18)
University 02 (1)
TTR (% INR control), n
TTR < 60 % 94 (47)
TTR 60–75 % 51 (25)
TTR > 75 % 56 (28)
Monthly income (USD), mean (SD) 416 (238)
OAK’s questions answered correctly, mean (SD) 63 (22)
OAK categories
<50 % (low level of knowledge) 59 (29)
50–75 % (moderate level of knowledge) 83 (42)
>75 % (high level of knowledge) 76 (29)
OAK, oral anticoagulation knowledge; SD, standard deviation; TTR, time within
therapeutic range
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Table 2 Percentage of correct answers in Brazilian version of OAK Test and the correlation values after exclusion of each item
(n = 201), 2015
Brazilian version of OAK Test





1. Missing one dose of Coumadin (warfarin):
1. Esquecer de tomar uma dose da varfarina:
Correct answer:
a. has no effect
b. can alter the drug’s effectivenessa
c. is permissible as long as you take a double dose the next time
d. is permissible as long as you watch which foods you eat
84 % 0.821
2. You can distinguish between different strengths of Coumadin (warfarin)
tablets by what?








3. A patient on Coumadin (warfarin) therapy
should contact the physician or healthcare provider who monitors it when:
3. O paciente que toma varfarina deve entrar em contato com o médico ou
quem acompanha o tratamento quando:
Correct answer:
a. another physician adds a new medication
b. another physician stops a current medication
c. another physician changes a dose of a current medication
d. all of the above
63 % 0.803
4. Occasionally eating a large amount of leafy greens vegetables while
taking Coumadin (warfarin) can:
4. Ocasionalmente comer uma grande quantidade de folhas verdes enquanto
toma varfarina pode:
Correct answer:
a. increase your risk of bleeding from Coumadin (warfarin)
b. reduce the effectiveness of the Coumadin (warfarin)
c. cause upset stomach and vomiting
d. reduce your risk of having a blood clot
51 % 0.815
5. Which of the following vitamins interacts with Coumadin (warfarin)?







6. When is it safe to take a medication that
interacts with Coumadin (warfarin)?
6. Quando é seguro tomar um medicamento que interage com a varfarina?
Correct answer:
a. if you take the Coumadin (warfarin) in the morning and the interacting
medication at night
b. if your healthcare provide is aware of the interaction and checks
your PT/INR (“Protime”) regularly
c. if you take your Coumadin (warfarin) every other day
d. it is never safe to take a medication that interacts with Coumadin (warfarin)
40 % 0.804
7. The PT/INR (“Protime”) test is:
7. O exame de RNI é:
Correct answer:
a. a blood test used to monitor your Coumadin (warfarin) therapy
b. a blood test that is rarely done while on Coumadin (warfarin)
c. a blood test that checks the amount of vitamin K in your diet
d. a blood test that can determine if you need to be on Coumadin (warfarin)
88 % 0.818
8. Coumadin (warfarin) may be used to:
8. A varfarina pode ser usada para:
Correct answer:
a. treat people that already have a blood clot
91 % 0.813
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Table 2 Percentage of correct answers in Brazilian version of OAK Test and the correlation values after exclusion of each item
(n = 201), 2015 (Continued)
b. treat people that have high blood sugar levels
c. treat people with high blood pressure
d. treat people with severe wounds
9. A patient with a PT/INR (“Protime”) value below their “goal range”:
9. Um paciente com o RNI abaixo da “faixa desejada”:
Correct answer:
a. is at an increase the risk of bleeding
b. is at an increase the risk of having a clot
c. is more likely to have a skin rash from the Coumadin (warfarin)
d. is more likely to experience side effects from Coumadin (warfarin)
67 % 0.803
10. Taking a medication containing aspirin or other non-steroidal anti-inflammatory
medications such as ibuprofen (Motrin®/Advil®) while on Coumadin (warfarin) will:
10. Tomar um medicamento que contenha ácido acetilsalicílico (AAS) ou outros
anti-inflamatórios não esteroides, como ibuprofeno, enquanto estiver tomando a varfarina irá:
Correct answer:
a. reduce the effectiveness of the Coumadin (warfarin)
b. increase your risk of bleeding from the Coumadin (warfarin)
c. cause a blood clot to form
d. require you to increase your dose of Coumadin (warfarin)
46 % 0.805
11. A person on Coumadin (warfarin) should seek immediate medical attention:
11. Uma pessoa que toma varfarina deve procurar atendimento médico imediatamente:
Correct answer:
a. if they skip more than two doses of Coumadin (warfarin) in a row
b. if they notice blood in their stool when going to the bathroom
c. if they experience a minor nosebleed
d. if they develop bruises on their arms or legs
50 % 0.807
12. Skipping even one dose of your Coumadin (warfarin) can:
12. Deixar de tomar uma única dose da varfarina pode:
Correct answer:
a. cause your PT/INR (“Protime”) to be above the “goal range”
b. increase your risk of bleeding
c. cause your PT/INR(“Protime”) to be below the “goal range”
d. decrease your risk of having a clot
58 % 0.811
13. Drinking alcohol while taking Coumadin
(warfarin):
13. Ingerir bebidas alcoólicas enquanto estiver em tratamento com a varfarina:
Correct answer:
a. is safe as long as you separate your dose of Coumadin (warfarin) and the alcohol
consumption
b. may affect your PT/INR (“Protime”)
c. does not affect your PT/INR (“Protime”)
d. is safe as long as you are on a low dose
84 % 0.819
14. Once you have been stabilized on the correct dose of Coumadin (warfarin),
about how often should your PT/INR (“Protime”) value be tested?
14. Uma vez que você tenha estabilizado sua dose correta da varfarina, com que
frequência o valor do seu RNI deve ser testado?
Correct answer:
a. once a week
b. once a month
c. once every other month
d. once every 3 months
65 % 0.816
15. It is important for a patient on Coumadin (warfarin) to monitor for signs
of bleeding:
15. É importante para um paciente em uso da varfarina estar atento a sinais
de sangramento:
Correct answer:
a. only when their PT/INR (“Protime”) is above the goal range
b. at all times
c. only when their PT/INR (“Protime”) is below the goal range
d. only when you miss a dose
56 % 0.804
16. The best thing to do if you miss a dose of
Coumadin (warfarin) is to?
16. A melhor coisa a ser feita se você esquecer de tomar uma dose da varfarina é?
Correct answer:
74 % 0.810
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performance of the instrument, supporting its validation
for use in Brazil.
The reliability of an instrument is related to the ability
to measure an attribute accurately, over time, and the
consistency and stability of the attribute measured [19].
In this sense, the Brazilian version of the OAK Test
retained the reliability and validity presented by the ori-
ginal English instrument. Reliability was confirmed by
internal consistency and test-retest measures and the
content, face [12], and validities were also confirmed.
In terms of the application of the OAK Test, good
internal consistency was observed as the temporal
stability ranged between good and perfect. These re-
sults demonstrate that the instrument in question is
reliable and has adequate temporal stability, corrobor-
ating the findings of the original study in which the
instrument was developed [8], and another study that
obtained similar results [11].
Through the initial hypothesis that there would be a
positive correlation, of moderate to strong intensity, be-
tween the correctness levels of the OAK Test and the
TTR values, the validity of the instrument was proven,
since there was a strong positive correlation (rs = 0.780).
This hypothesis was also confirmed by other investiga-
tions, demonstrating that the greater the patient’s know-
ledge about treatment with warfarin, the better was the
control of oral anticoagulation, as expressed by higher
TTR values [11, 20]. We observed that formal education
and income showed a weak association with the OAK
Test, which is similar to the results of other studies that
have not demonstrated significant associations between
knowledge and these variables as well [8, 21].
By applying the OAK Test, it was possible to verify the
level of knowledge of the patients treated with warfarin
in a public hospital in Brazil. The average correctness of
the test answers was 63 %, which is in line with that
found in other studies [8, 22]; besides 71 % of patients
had average or high level of knowledge. However, a simi-
lar study conducted in Malaysia identified an average of
only 11.2 % of correctness [11]. Studies that used other
tests also revealed differences in the level of knowledge
of participants. Both low levels of knowledge [23, 24],
Table 2 Percentage of correct answers in Brazilian version of OAK Test and the correlation values after exclusion of each item
(n = 201), 2015 (Continued)
a. double up the next day
b. take the next scheduled dose and tell your healthcare provider
c. call your healthcare provider immediately
d. discontinue Coumadin (warfarin) altogether
17. When it comes to diet, people taking Coumadin (warfarin) should:
17. Quando se trata da alimentação, as pessoas que tomam varfarina devem:
Correct answer:
a. never eat foods that contain large amounts of vitamin K
b. keep a diary of all of the foods they eat
c. be consistent and eat a diet that includes all types of food
d. increase the amount of vegetables they eat
39 % 0.806
18. Each time you get your PT/INR (“Protime”) checked, you should:
18. Cada vez que você fizer seu exame RNI, você deve:
Correct answer:
a. skip your dose of Coumadin (warfarin) on the day of the test
b. avoid eating high fat meals on the day of the test
c. avoid foods high in vitamin K on the day of the test
d. let your doctor know if you missed any doses of Coumadin (warfarin)
44 % 0.807
19. Which of the following over-the-counter products is most likely to
interact with Coumadin (Warfarin)?
19. Qual dos seguintes produtos, que não precisam de receita, é mais
provável de interagir com a varfarina?
Correct answer:





20. A patient with a PT/INR (“Protime”) value above the “goal range”:
20. Um paciente com um valor de RNI acima da “faixa desejada”:
Correct answer:
a. is at an increased risk of having a clot
b. is more likely to have drowsiness and fatigue from Coumadin (warfarin)
c. is at an increased risk of bleeding
d. is less likely to experience side effects from Coumadin (warfarin)
73 % 0.802
aThe correct answer for each question is highlighted in bold. OAK Oral Anticoagulation Knowledge, INR international normalized ratio, PT prothrombin time
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and good levels of knowledge were observed [10, 25].
Such differences may be related to sociodemographic and
clinical particularities of the patients included, the quality
of anticoagulation services, or methodological differences
employed in the application of knowledge tests.
In the present study, it was observed that a deficit in
knowledge about the drug and dietary interactions with
warfarin correlated with a correctness rate of less than
50 %. These data are in line with those of another study
carried out in an anticoagulation clinic, which showed
meaningful gaps in the knowledge regarding the drug
and dietary interactions [22]. These findings signal the
importance of implementing educational strategies to im-
prove the understanding of these issues using approaches
that can contribute to modifying patients’ behavior re-
garding self-care and appropriate lifestyle choices.
Most patients had TTR lower than 60 %, which is a
worrisome result since the rates of bleeding and mortal-
ity are significantly higher in patients with TTR < 60 %
when compared to those with TTR > 75 % [7]. Labora-
torial monitoring is necessary to guide dose adjustments
in order to achieve INR target. Interventions focused on
INR control, and consequent TTR elevation, contribute
to the increase of effectiveness of drug therapy and the
minimization of adverse drug events. In this sense, the
use of valid and reliable instruments allow health teams
to evaluate the level of knowledge of patients and iden-
tify knowledge deficits on important aspects related to
the treatment with warfarin substantiating appropriate
decision for patient management [1].
Regarding the limitations of this study, it is noteworthy
that, as there are no instruments aimed at evaluating pa-
tients’ knowledge about therapy with warfarin already
validated for the Brazilian population, the criterion valid-
ity could not be established, as this would have required
using a gold standard instrument. Added to this, the fact
that although the sample size was sufficient to demon-
strate the performance of the instrument, this relatively
small number of individuals can also limit the ability to
generalize the results for different groups of Brazilian
patients on warfarin.
As another limitation of the study, OAK Test was ori-
ginally designed to be self-administered by individuals
with at least seven years of education. However, due to
the low level of education presented by several individ-
uals enrolled in this study, we preferred to administer
the instrument by patient interview, which has extended
the time of application.
However, the use of a rigorous methodological process
to evaluate the psychometric properties of the Brazilian
version of the OAK Test tried to maintain the reliability
and validity of the original instrument in English. In
addition, this instrument is useful, quick, and easy-to-
apply in clinical practice, by means of individual inter-
views with patients with different levels of education.
Based on a previous publication [12] we identified good
content and face validity of the instrument. The instru-
ment was proved to be effective in assessing what it pro-
poses to measure, and that most of the items analyzed
are relevant. This finding is in agreement with that of
other studies with similar goals [8, 11]. Item 2 of the in-
strument was a reason of debate among the authors.
Most of the population studied uses only the 5 mg war-
farin tablet that belongs to the list of drugs distributed
by the National Health System in Brazil, and that is not
distinguishable by the color that identifies the drug con-
centration as it happens in the US. Thus, participants
may present difficulties in understanding this question.
However, we made a decision to retain Item 2 in the
final version to provide a broader scope of the instru-
ment to be used not only by public health services but
also by private institutions where warfarin brands that
allow patients to distinguish different drug concentra-
tions by color may be preferably prescribed.
The results of the test may assist the stratification of pa-
tients and the improvement of planning and individualization
of educational practices according to the needs of the pa-
tients. The need for further studies to check the performance
of the instrument in individuals with characteristics different
from the study group is indicated.
Table 3 Temporal stability of questions Brazilian version of OAK
Test, 2015





















Praxedes et al. Health and Quality of Life Outcomes  (2016) 14:96 Page 7 of 9
Conclusion
The Brazilian version of the OAK Test showed good
psychometric properties and was found to be a reliable
and valid instrument for evaluating the knowledge of
Brazilian patients on oral anticoagulant therapy using
warfarin. The results generated with the use of the in-
strument may be incorporated into the practice of public
health care, in order to structure health education activ-
ities to ensure improvement in the knowledge of the
therapy proposed, which may help increase the effective-
ness and safety of the treatment.
The use of the instrument will also aid the analysis of
the relationship between the knowledge of the patients
and the quality of the anticoagulation treatment using
warfarin, as well as the comparison of research findings
between different countries. It favors, then, the commu-
nication between health professionals and patients, and
contributes to the rapid identification of problems and
priority needs, as well as to decision-making.
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